After finishing at $88.65 in the prior trading day, BioNTech SE ADR (NASDAQ: BNTX) closed at $87.01, down -1.85%. In other words, the price has decreased by -$1.64 from its previous closing price. On the day, 568631 shares were traded.
Ratios:
Our goal is to gain a better understanding of BNTX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.76. For the most recent quarter (mrq), Quick Ratio is recorded 9.26 and its Current Ratio is at 9.43. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on February 23, 2024, initiated with a Outperform rating and assigned the stock a target price of $127.
JP Morgan Downgraded its Neutral to Underweight on December 01, 2023, whereas the target price for the stock was revised from $106 to $99.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 20.98B and an Enterprise Value of 3.25B. As of this moment, BioNTech’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.22. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.02 while its Price-to-Book (P/B) ratio in mrq is 0.92. Its current Enterprise Value per Revenue stands at 0.85 whereas that against EBITDA is 2.99.
Stock Price History:
Over the past 52 weeks, BNTX has reached a high of $131.52, while it has fallen to a 52-week low of $85.21. The 50-Day Moving Average of the stock is 92.20, while the 200-Day Moving Average is calculated to be 102.02.
Shares Statistics:
The stock has traded on average 634.94K shares per day over the past 3-months and 433.07k shares per day over the last 10 days, according to various share statistics. A total of 237.73M shares are outstanding, with a floating share count of 237.71M. Insiders hold about 0.01% of the company’s shares, while institutions hold 17.85% stake in the company. Shares short for BNTX as of Mar 15, 2024 were 3.08M with a Short Ratio of 4.85, compared to 3.01M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.30% and a Short% of Float of 6.43%.
Earnings Estimates
Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of -$1.17 for the current quarter, with a high estimate of $0.17 and a low estimate of -$2.99, while EPS last year was $2.25. The consensus estimate for the next quarter is -$1.92, with high estimates of -$0.29 and low estimates of -$3.24.
Analysts are recommending an EPS of between $4.31 and -$4.04 for the fiscal current year, implying an average EPS of -$1.62. EPS for the following year is -$1.42, with 13 analysts recommending between $4.56 and -$6.21.
Revenue Estimates
8 analysts predict $374.39M in revenue for the current quarter. It ranges from a high estimate of $869.78M to a low estimate of $174.46M. As of the current estimate, BioNTech SE ADR’s year-ago sales were $1.4B, an estimated decrease of -73.30% from the year-ago figure.
A total of 16 analysts have provided revenue estimates for BNTX’s current fiscal year. The highest revenue estimate was $4.54B, while the lowest revenue estimate was $2.33B, resulting in an average revenue estimate of $3.03B. In the same quarter a year ago, actual revenue was $4.15B, down -26.90% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $3.03B in the next fiscal year. The high estimate is $4.28B and the low estimate is $1.77B. The average revenue growth estimate for next year is down -0.10% from the average revenue estimate for this year.
